An Introduction to Ovarian Cancer
Before 2016 the prognosis for patients with ovarian cancer was poor, and treatment options were limited. However, the introduction of bevacizumab followed by PARP inhibitors transformed outcomes in patients with BRCA1/2 mutation. Anti-angiogenic agents, immuno-oncology agents, combinations of these agents and hyperthermic intraperitoneal chemotherapy are currently being investigated and show promise for the future.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever-changing landscape.
Ovarian Cancer Content
Ruth Perets, AACR 2022: Vibostolimab/Pembrolizumab Coformulation for the Treatment of Ovarian Cancer Naive to PD-1/PD-L1 Inhibitors
We were delighted to speak with Dr. Ruth Perets (Rambam Health Care Campus, Haifa, Israel) about the efficacy and safety findings of the phase 1 study comparing vibostolimab (vibo) plus pembrolizumab (pembro) given sequentially to the coformulation of vibo/pembro in ovarian cancer naive to PD-1/PD-L1 inhibitors. The abstract ‘Safety and efficacy of vibostolimab (vibo) plus […]
Domenica Lorusso, ESMO 2021: Relacorilant in Combination with Nab-paclitaxel for Patients with Recurrent Platinum-resistant Ovarian Cancer
touchONCOLOGY joins Dr Domenica Lorusso (Rome, Italy), to discuss the improvements in progression-free survival in patients with recurrent platinum-resistant ovarian cancer using relacorilant in combination with nab-paclitaxel. (NCT03776812) Question Please summarise the randomized, open-label, phase II study presented at ESMO 2021 exploring progression-free survival in patients with recurrent platinum-resistant ovarian cancer using relacorilant, a selective […]
Shibani Nicum, ESMO 2021: First Results of the OCTOVA Trial
touchONCOLOGY joins Dr Shibani Nicum (University College London, UK) at ESMO 2021 to present the first results of the OCTOVA trial of olaparib compared to weekly paclitaxel or olaparib plus cediranib in patients with platinum-resistant ovarian cancer. Questions 1. What are the unmet needs in the treatment of ovarian cancer patients who relapse within 12 […]
Maintenance Treatment for Recurrent Ovarian Carcinoma – Evidence Supporting the Efficacy and Safety of PARP Inhibitors
European Oncology & Haematology. 2019;15(1):29–40 DOI: https://doi.org/10.17925/EOH.2019.15.1.29
Worldwide, ovarian cancer is the seventh most common cancer and the eighth most common cause of cancer death in women.1 The GLOBOCAN study estimated there were 239,000 new cases in 2012 and 152,000 deaths due to this disease. There are nearly 600,000 women living within 5 years of an ovarian cancer diagnosis.1 In the EU, age-adjusted ovarian […]
Advances in the Treatment of Endometrial and Ovarian Cancer
Oncology & Hematology Review. 2019;15(1):23–4 DOI: https://doi.org/10.17925/OHR.2019.15.1.23
Gynecological malignancies can be difficult to treat. Ovarian cancer carries with it the worst prognosis of all gynecological cancers. Approximately 75% of patients with epithelial ovarian cancer are diagnosed with advanced disease which is curable only in a minority of cases, resulting in a 5-year overall survival rate of only 20–30%. However, survival at all […]
Results from SOLO-1 Presented at ESMO 2018 – Impressive Findings for Olaparib Maintenance Therapy in Patients with Newly-diagnosed, Advanced BRCA-mutated Ovarian Cancer
Ovarian cancer is a leading cause of cancer death in women worldwide, with almost 300,000 cases diagnosed in 2018.1 If diagnosed and treated at stage I, the 5-year relative survival rate is 92%. However, only about 15% of ovarian cancers are diagnosed at this stage, and the prognosis for advanced ovarian cancer is bleak: 5-year […]
Olaparib as a Maintenance Therapy for Ovarian Cancer and its use in BRCA-related Metastatic Breast Cancer
Recent results from trials with olaparib, a potent oral poly(ADP-ribose) polymerase inhibitor, are discussed in this Insight. Positive data and regulatory approvals are demonstrating that targeting the underlying genetic causes of a cancer can be a powerful tool for the development of new treatments with efficacy across different cancer types.
Bevacizumab in the Management of Epithelial Ovarian Cancer
Oncology & Hematology Review (US), 2013;9(2):129–131 DOI: https://doi.org/10.17925/OHR.2013.09.2.129
Epithelial ovarian cancer has long been recognized as being highly sensitive to cytotoxic chemotherapy, with anticipated objective response to platinum-based chemotherapy of approximately 70-85%1. Furthermore, overall survival (OS) for women presenting with advanced disease has been documented to have improved over the past few decades,2 although unfortunately the majority of responding patients ultimately experience recurrence […]
Squamous Cell Carcinoma Arising in a Mature Cystic Teratoma of the Ovary: A Case Series and Review of the Literature
European Oncology & Haematology, 2013;9(1):17–20 DOI: https://doi.org/10.17925/EOH.2013.09.1.17
Mature cystic teratomas (also called dermoid cysts) account for about 30–45 % of all ovarian neoplasms and around 60 % of all benign tumours arising in the ovary.1 Malignant transformation of the various mature tissue components of a dermoid cyst is rare and the reported incidence is 0.17–1.4 %.2,3 Squamous cell carcinoma (SCC), arising from […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!